Qilu Puget Sound Biotherapeutic

Qilu Puget Sound Biotherapeutic Corp. is a Seattle-based biotechnology company serving as the primary North American research and development hub for Qilu Pharmaceutical. The company specializes in the discovery and development of innovative biologics, with a particular focus on next-generation oncology treatments such as bispecific antibodies and antibody-drug conjugates (ADCs). By integrating local expertise in the Puget Sound region with the global manufacturing and clinical resources of its parent company, QPSB aims to advance a robust pipeline of therapies targeting unmet needs in cancer care. Their lead programs include novel immune checkpoint inhibitors and targeted therapies for solid tumors. The center plays a critical role in Qilu's global strategy to transition from a generics-focused manufacturer to an innovation-driven biopharmaceutical leader.